JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
J Clin Invest
.
2018 Oct 1;128(10):4743.
doi: 10.1172/JCI124920.
Epub 2018 Sep 17.
Authors
Anna Sophia McKenney
,
Allison N Lau
,
Amritha Varshini Hanasoge Somasundara
,
Barbara Spitzer
,
Andrew M Intlekofer
,
Jihae Ahn
,
Kaitlyn Shank
,
Franck T Rapaport
,
Minal A Patel
,
Efthymia Papalexi
,
Alan H Shih
,
April Chiu
,
Elizaveta Freinkman
,
Esra A Akbay
,
Mya Steadman
,
Raj Nagaraja
,
Katharine Yen
,
Julie Teruya-Feldstein
,
Kwok-Kin Wong
,
Raajit Rampal
,
Matthew G Vander Heiden
,
Craig B Thompson
,
Ross L Levine
PMID:
30222137
PMCID:
PMC6159958
DOI:
10.1172/JCI124920
No abstract available
Publication types
Published Erratum
Grants and funding
K12 CA184746/CA/NCI NIH HHS/United States
P30 CA008748/CA/NCI NIH HHS/United States